Tumeh et al. initially reported that PD-1 blockade was much less effective in melanoma or NSCLC patients with LM (ORR and median PFS of 47.5% and 5.1 months for patients with LM compared to 70.8% and 20.1 months for those without LM) [188]. Here, PDCD1 is linked to melanoma.